BIOtechNOW News & Videos - Business Development Sponsor Logo

Health Care

Videos

Keynote speaker Josh Sommer was recently named one of Forbes 30 Under 30 in Science and Healthcare. He discusses his rare cancer diagnosis. 
Scott Williams, VP, Men's Health Network
George Vradenburg, USAgainstAlzheimer's
Chris Garabedian, CEO, Sarepta Therapeutics
Briggs Morrison, EVP of Global Medicine Development, AstraZeneca
Jennifer Griffiths, Chief Mission Officer of the Arthritis Foundation.
Dr. Robin Robinson, Director, BARDA
Ana Fadich, VP, Men's Health Network
Medhat Gorgy, President and CEO PYRAMID LABORATORIES
Chris Yochim - AstraZeneca
Dr. Robin Robinson, Director, BARDA
Kathleen Ruddy, CEO St. Baldricks Foundation
Rachel King, CEO, GlycoMimetics (BIO Chair) with Kate Neville (Women in Bio)
Patrick Livney
Rogerio Vivaldi
Alicia Loffler Interview by Sonia Kim
Kathleen Ruddy, CEO St. Baldricks Foundation
Dr. Heather Snyder, Alzheimer's Association
Dr. Richard Mohs, Distinguished Research Fellow, Eli Lilly
Dr. Richard Mohs, Distinguished Research Fellow, Eli Lilly
Dr. Stephen Spielberg, former Deputy Commissioner of the FDA
Adina Mangubat, President and CEO - Sprial Genetics

Articles from BioTechNow

The Affordable Care Act is Here to Stay

Posted: 4/23/23013 By: Adina Mangubat


The Patient Protection and Affordable Care Act (ACA) of 2010 includes provisions that could lead to new and improved treatments, cures and cost savings for patients. All of these changes, however, will impact the biotechnology industry and the future of patient access to needed medicines. In an expert panel at the 2013 BIO International Convention moderated by BioCentury’s Steve Usdin, multiple stakeholders addressed key elements of the ACA focused on both the value the ACA will offer as well as practical issues surrounding implementation. Usdin was joined by Jonathan Blum, Director, Center for Medicare, Centers for Medicare and Medicaid Services; Marc Boutin, Executive Vice President & COO, National Health Council; ...

Read More >

Biopharmaceuticals and Accountable Care Organizations: Balancing Cost and Quality

Publish Date: 4/29/2013, Created By: BIOtechNOW Editor


As biopharmaceutical manufacturers consider the new reality of accountable care organizations (ACOs) and the impact on their businesses, they must be ready to demonstrate the value of their products in ways that recognize the fine balance of cost and quality that ACO and ACO-like models seek to achieve. According to panelists speaking at the 2013 BIO International Convention session entitled, “Accountable Care Organization (ACO) Framework for Biopharmaceuticals,” there are three primary considerations when it comes ...

Read More >

The Affordable Care Act is Here to Stay

Publish Date: 4/25/2013, Created By: BIOtechNOW Editor


The Patient Protection and Affordable Care Act (ACA) of 2010 includes provisions that could lead to new and improved treatments, cures and cost savings for patients. All of these changes, however, will impact the biotechnology industry and the future of patient access to needed medicines. In an expert panel at the 2013 BIO International Convention moderated by BioCentury’s Steve Usdin, multiple stakeholders addressed key elements of the ACA focused on both the value the ACA ...

Read More >

The Rise of Specialty Pharmaceuticals

Publish Date: 4/24/2013, Created By: BIOtechNOW Editor


Fact: Specialty pharmaceuticals represented nearly 25 percent of all drug spending last year. By 2018, it’s estimated they’ll account for nearly half of the 100 top-selling medications on the market. With an average cost for a specialty medical therapy hovering around $35,000 to $75,000 per patient per year, this is an area that is getting the attention of top industry players – from biopharma who see the market opportunity to healthcare payors like health plans ...

Read More >

The Ethics of the Market Access Debate

Publish Date: 4/24/2013, Created By: BIOtechNOW Editor


At the core of the market access conversation lies the question of value. How much do we value two years added to the end of an 80-year-old’s life? How do we put a dollar amount on a medicine that prevents a rare disease patient, who may only live to age 20 regardless of receiving treatment, from losing her ability to walk? How can we define metrics to measure the cost of a child with a ...

Read More >

Managed Entry Trumps Risk Sharing

Publish Date: 4/24/2013, Created By: BIOtechNOW Editor


Since 2000, pharmaceu-tical and biotech companies have engaged in agreements with government and private payers across the world to gain market access for their innovative drugs despite struggles to qualify for formal reimbursement criteria, such as the cost effectiveness threshold from NICE in the UK. These agreements, usually referred to as “risk sharing” agreements, have had a wide variety of structures but usually do not involve any sharing of risk, as the name misleadingly suggests. ...

Read More >

Alzheimer’s Disease “Robs You of Everything”

Publish Date: 4/24/2013, Created By: BIOtechNOW Editor


George Hendrick and his wife, Mary Lee, experienced the typical highs and lows of parenthood as they raised nine children in New Lenox, a south suburb of Chicago. After the couple’s nest was nearly empty, in what was supposed to be their golden years, George was told he had memory and thinking problems, and later, Alzheimer’s disease. George’s long tenure as a Will County police officer was cut short. He could no longer carry a gun, and ...

Read More >

Biomedical R&D in the 21st Century

Publish Date: 4/23/2013, Created By: BIOtechNOW Editor


Reflecting back upon my career,  I recognize the importance academic-industry research partnerships played in shaping my philosophy as a scientist and research leader.  Something deeply fulfilling happens when basic and applied scientists ally, and our individual passion to make a difference in the life of a patient merges into a community effort. We are moving ever closer to solving some of the toughest biomedical challenges of our time.  But this is also an era of ...

Read More >

#BIO 2013: Open Innovation and Biopharmaceutical R&D

Publish Date: 4/23/2013, Created By: BIOtechNOW Editor


In these changing times, the concept of Open Innovation is one that we at AstraZeneca have fully embraced. By sharing new ideas and enabling scientific innovation to cross boundaries between companies, academia, government and non-profit organizations, we can accelerate new ideas into innovative medicines. An Open Innovation discussion at BIO I will discuss the importance that AstraZeneca places on Open Innovation today at this year’s BIO International Convention. An interactive session will include a panel discussion and presentations ...

Read More >

Q & A with Eli Lilly’s Eric Siemers

Publish Date: 4/23/2013, Created By: BIOtechNOW Editor


In October 2012, Eli Lilly and Company released results of its Expedition trials, two Phase 3, double-blind, placebo-controlled studies of the anti-amyloid antibody solanezumab, in patients with mild-to-moderate Alzheimer’s disease. Although cognitive decline was slowed in patients with early stage disease in one trial, and there were also positive signs from the other trial, those findings were not statistically significant. But a secondary analysis conducted independently by a panel of academic researchers pooled data from ...

Read More >

New Challenges in the Fast Changing Landscape of Bioinformatics

Publish Date: 4/23/2013, Created By: BIOtechNOW Editor


The world of DNA sequencing and bioinformatics has evolved at a staggering pace. In 2009, the biggest problem for researchers was creating an efficient solution for sequencing DNA. At that time, sequencing cost of $100,000 for a single human and took 30 days of chemical processing to produce the raw sequencing output. In four years, DNA sequencing technology has advanced rapidly, outpacing even Moore’s Law. Today, researchers can sequence a whole human genome for about ...

Read More >